Original Research

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study

Ruggiero A, Fabbrocicni G, Cacciapuoti S, Potestio L, Gallo L, Megna M

Clinical, Cosmetic and Investigational Dermatology 2023, 16:529-536

Published Date: 27 February 2023